Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

MeSH terms

• Anticoagulants / standards
• Anticoagulants / therapeutic use*
• Bias
• Case Management
• Clinical Trials, Phase III as Topic / methods
• Clinical Trials, Phase III as Topic / standards
• Cost-Benefit Analysis
• Double-Blind Method*
• Fibrinolytic Agents / standards
• Fibrinolytic Agents / therapeutic use
• Heparin / therapeutic use
• Heparin, Low-Molecular-Weight / therapeutic use
• Humans
• Patient Selection
• Professional Practice
• Prothrombin Time / instrumentation
• Quality of Life
• Randomized Controlled Trials as Topic / methods*
• Randomized Controlled Trials as Topic / standards
• Thrombophilia / drug therapy
• Treatment Outcome
• Vitamin K / antagonists & inhibitors